China Eager To Establish Pharmacovigilance System – SFDA Officials
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - In an effort to ensure drug safety, China will establish a pharmacovigilance system and will continue to improve its adverse drug reaction reports system, said Yan Ming, director of the drug re-evaluation division under China's State FDA drug safety and inspection department, during an international conference on post-market drug safety Oct. 29 in Shanghai
You may also be interested in...
Pharmacovigilance Is A Global Safety Issue – DIA Singapore Conference
Pharmacovigilance and risk management is a global safety issue, and the quality of safety data that is being retrieved is more important than where the data is coming from, according to consultant and former U.S. FDA MedWatch Medical Director Stephen Goldman
Pharmacovigilance Is A Global Safety Issue – DIA Singapore Conference
Pharmacovigilance and risk management is a global safety issue, and the quality of safety data that is being retrieved is more important than where the data is coming from, according to consultant and former U.S. FDA MedWatch Medical Director Stephen Goldman
Focused On Globalization, Shanghai FDA Will Hold International Forum On Drug Safety And Regulatory Change
BEIJING - In an effort to fast-forward the globalization of China's drug laws and utlimately boost its exports of pharmaceuticals, the Shanghai FDA is partnering with a U.S.-based law firm to co-host its first international forum on drug safety and regulatory change